PROVECTUS BIOPHARMACEUTICALS, INC.
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2021 | — | $-4.2M | $683.0K |
| FY2022 | — | $-6.2M | $21.6K |
| FY2023 | — | $-7.6M | $76.6K |
| FY2024 | — | $-6.0M | $307.4K |
| FY2025 | — | $-6.3M | $251.3K |
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2021 | — | $-4.2M | $683.0K |
| FY2022 | — | $-6.2M | $21.6K |
| FY2023 | — | $-7.6M | $76.6K |
| FY2024 | — | $-6.0M | $307.4K |
| FY2025 | — | $-6.3M | $251.3K |